Archives
Two Therapeutic Targets Identified for Deadly Lung Cancer
(July 26, 2019) The vast majority of deadly lung cancer cases (85 percent) are termed non-small-cell lung carcinomas (NSCLCs), which often contain a mutated gene called LKB1. Salk Institute researchers have now discovered precisely why inactive LKB1 results in cancer development. The surprising results, published in the online version of Cancer Discovery on July 26, 2019, highlight how LBK1 communicates with two enzymes that suppress inflammation in addition to cell growth, to block tumor growth. The findings could lead to new therapies for NSCLC.
Latest Research Articles
Antarctic: The IceCube Neutrino Experiment is Growing
CBD Oil & The Endocannabinoid System
Underwater Glacial Melting Occurring Much Faster than Predicted
Finnish Company Uses NASA’s Concept to Create Food from Thin Air
Electricity-Driven Undersea Reactions May Have Been Important For the Emergence of Life
3D-Printed Pill Samples Gut Microbiome to Aid Diagnosis and Treatment
ICR Claims New Gene Test Could Detect Prostate Cancer Patients
Microrobots Show Promise for Treating Tumors
Cold, Dry Planets Could Have a Lot of Hurricanes
Eco-Friendly Home Cleaning Products
DNA Testing Companies: What They Can and Cannot Reveal about Your Ancestry
Microfluidics Device Helps Diagnose Sepsis in Minutes
MOST POPULAR
-
Why Is Arctic Ice Melting So Much Faster Than Climate Models Ever Predicted?
-
Polar Bears Face Dire Climate Threats: Arctic Melting Crushes Habitat, Adaptation Struggles to Save Them
-
Why Do Cats Drag Dead Preys Home? Expert Insights Decode Feline Hunting Instincts
-
How to Save Bird Populations: Threats, Bird Migration Challenges, and Winning Avian Conservation Strategies
-
Stopping Wildlife Habitat Loss: Beat Deforestation Effects and Urban Sprawl Threats
